secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001193125-23-066144
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen terminates $28.5B Horizon bridge facility, enters new $4B revolver
------------------------------------------------------------------------

- Bridge credit facility (originally $28.5B) for Horizon Therapeutics acquisition terminated March 9, 2023 after reductions from $4B term loan and $23.8B senior note proceeds.
- New $4.0B revolving credit agreement signed with 5-year initial term, extendable up to two additional years, for general corporate purposes and commercial paper backstop.
- Interest on revolver advances is Adjusted Term SOFR plus 0.68%-1.10% (or base rate plus 0.00%-0.10%) depending on Amgen's senior debt rating.
- Company states sufficient liquidity from term loan, note proceeds, and cash to complete Horizon acquisition; remaining bridge commitments were not needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000119312523066144/0001193125-23-066144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000119312523066144/d466407d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-066144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer